Search

Your search keyword '"Alessandra Fabi"' showing total 353 results

Search Constraints

Start Over You searched for: Author "Alessandra Fabi" Remove constraint Author: "Alessandra Fabi"
353 results on '"Alessandra Fabi"'

Search Results

1. Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

2. Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients

3. Transient splicing inhibition causes persistent DNA damage and chemotherapy vulnerability in triple-negative breast cancer

4. TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication

5. Fatigue in patients with metastatic breast cancer undergoing single-agent taxane-based chemotherapy: a real-world data global network

6. Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis

7. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world

8. Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

9. Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

10. Follow-up of breast cancer: why is it necessary to start a Consensus in 2024?

11. Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study

12. Molecular Profile and Matched Targeted Therapy for Advanced Breast Cancer Patients

13. Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study

14. Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer

15. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study

16. Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

17. Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials

18. Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy

19. Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

20. The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysisResearch in context

21. Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicine

22. Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report

23. Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer

24. Paget’s disease of the breast: Our 20 years’ experience

25. Impact of epilepsy and its treatment on brain metastasis from solid tumors: A retrospective study

26. Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice

27. Definition of a tool to assess shared decision‐making (SDM) on women with breast cancer: A value‐based approach

28. Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach

29. The immersive experience of virtual reality during chemotherapy in patients with early breast and ovarian cancers: The patient’s dream study

30. Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial

31. How Dual-Energy Contrast-Enhanced Spectral Mammography Can Provide Useful Clinical Information About Prognostic Factors in Breast Cancer Patients: A Systematic Review of Literature

32. PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

33. Use of rehabilitation pathways in women with breast cancer in the first 12 months of the disease: a retrospective study

34. Loco-regional adjuvant radiation therapy in breast cancer patients with positive axillary lymph-nodes at diagnosis (CN2) undergoing preoperative chemotherapy and with complete pathological lymph-nodes response. Development of GRADE (Grades of recommendation, assessment, Development and Evaluation) recommendation by the Italian Association of radiation therapy and Clinical Oncology (AIRO)

35. Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study

36. Corrigendum: Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors

37. Narrative medicine: feasibility of a digital narrative diary application in oncology

38. Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors

39. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

40. Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification

41. Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study

42. Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations

43. Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.

44. Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.

45. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.

46. Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.

47. Abstract OT1-16-01: Trial In Progress: An Evaluation of FACIT-Fatigue in Patients with Locally Advanced or Metastatic Breast Cancer receiving Treatment with Taxane-based Chemotherapy

48. Abstract P1-11-04: Assessing the clinico-pathological characteristics of HER2 positive metastatic breast cancer patients experiencing radiologic complete response in a nationwide cohort

49. Abstract OT1-22-01: Liquid biopsy and Ado-trastuzumab emtansine (T-DM1): drug-resistance traits in the blood of HER2-positive metastatic breast cancer patients

50. Abstract P5-07-09: Fatigue in patients with locally advanced or metastatic breast cancer undergoing single-agent taxane-based chemotherapy: de novo versus relapsed

Catalog

Books, media, physical & digital resources